Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Q1 Revenues Surge Amid Widened Losses

NEW YORK, April 24 - Ciphergen Biosystems reported a sharp increase in year-over-year revenue for the first quarter today, and widened its losses slightly.

 

The Fremont, Calif., company's revenues for the quarter rose to $12.8 million, from $6.8 million in the first quarter of 2002. The company said the 88 percent revenue surve came from increased sales of its ProteinChip systems and arrays, and its BioSepra process proteomics products; as well as increased service activities.

 

Ciphergen's net losses widened to $9.1 million for the first quarter, from $7.6 million in the year-ago quarter.

 

R&D expenses increased to $6.4 million, from $3.9 million in the first quarter of 2001.

An increase in sales, general, and administrative expenses accounted for the remainder of the rise in expenses to $17.1 million, from $11.8 million in the previous year's period, and consequent widening of losses.

 

As of March 31, Ciphergen had $36.3 million in cash, cash equivalents and investments, compared to $42.5 million at the end of March 2002.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.